Anti-Allergic Activity of Matricuria Recutit Linn

ANTI-ALLERGIC ACTIVITY OF BUCHNANIA LANZAN SPRENG. IN MAST CELL MEDIATED ALLERGIC MODELSProtocol of Dissertation SubmittedByMr. VIJAYKUMAR SHEVALEToRajiv Gandhi University of Health Sciences Bangalore, Karnataka.Under the guidance of Dr. I. S. MUCHCHANDI Principal and professorDepartment of Pharmacology, HANAGAL SHRI KUMARESHWAR COLLEGE OF PHARMACY, BAGALKOT- 587101, KARNATAKA. (2012-13)1RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCESKARNATAKA-BANGALOREANNEXURE IIPROFORMA FOR REGISTRATION OF SUBJECTS FORDISSERTATION1. Name of the Candidate and Address VIJAYKUMAR SHEVALE DEPARTMENT OF PHARMACOLOGY, H.S.K. COLLEGE OF PHARMACY, B.V.V.S CAMPUS, BAGALKOT-587101, KARNATAKA.2. Name of the Institution H.S.K. COLLEGE OF PHARMACY, B.V.V.S CAMPUS, BAGALKOT-587101, KARNATAKA.3. Course of Study and Subject MASTER OF PHARMACY IN PHARMACOLOGY4. Date of Admission to Course 16 Augast 20125. Title of topic: Anti-allergic activity of Buchnania lanzan Spreng. in mast cell mediated allergic models.2 6. Brief resume of the intended work 6.1 Need for the study:Immediate or type I, hypersensitivity is a rapidly developing immunologic reaction occurring within minutes after the combination of an antigen with antibody to mast cell in individuals previously sensitized to the antigen. These reactions are called allergic reactions and antigens eliciting them are called as allergens. Allergic reaction may occur as two types: Systemic reaction and local reaction usually follows injection of antigen to which host has become sensitized often with in a minutes, a state of shock is produced which is sometimes fatal. The nature of local reaction varies depending on portal entry of allergen and may take the form of localized cutaneous swelling (skin allergy), nasal and conjunctival discharge (allergic rhinitis & conjunctivitis), hay fever, bronchial asthma in which mast cells are the principal target cells for the immediate hypersensitivity1. As part of allergic response to an antigen, antibodies are generated and bind to the surface of mast cell via high affinity Fc receptors that are specific for IgE. Mast cells release histamine during these reactions. Mast cell mediators of inflammatory processes are histamine,2 proteases, LTC4, LTB4, PGD2, platelet activating factor . Mast cell degranulation is believed to be involved in the pathophysiology of CHF, asthma, allergic hypersensitivity reaction and inflammation. The modern medicines available as anti-allergic drugs include disodium cromoglycate but these drugs are associated with unwanted effects including local irritation, transient bronchospasm. These drugs are also restricted to use in pregnancy and prolonged use3.However, there are several plant-derived preparations in the ancient text of Ayurveda andSiddha for the treatment of allergic conditions including asthma. With continuation of new drug discovery, plants or their preparation scientifically to prove for their clinical applicability is required. In this view the present study has been selected for evaluation of Buchnania lanzan for its anti-allergic property in compound 48/80 induced allergic models.6.2 Review of literature:Plant profile-Title of plant : Buchnania lanzan Spreng. 3 Family : AnacardiaceaeSynonyms : Char, chironji, Almondette Tree, Murkali, Nurkale. Habitat : Hill Plant, Plain Land commonly found throughout the greater part of India (400-500 rpm) discarding the supernatant and taking the pellet of mast cells into the medium.Mast cells from the control group and treated group were incubated with compound 48/80(1µg/ml) at 37oc for 10 min. After incubation, mast cells were stained with toluidine blue (0.1%) and percent of protection against degranulation was counted under high-power microscope(45x)15.7.3.3 Blood histamine Determination:The histamine in blood was estimated by o-phthalaldehyde method by using fluorimetrically16.2 ml of aqueous phase of aliquot was taken, mixed 0.1 ml of OPT reagent and then added 0.2 ml of 3N HCL. The fluorescence of acidified solution was stable for atleast 90 min. The fluorescence intensity was proportional to histamine concentration over the range 0.005 to0.5µg/ml.7.3.4 Antianaphylactic activity:The compound 48/80 induced anaphylactic reaction is examined. Mice were given an injection(ip) of 8mg/kg of mast cell degranulation compound 48/80. Buchnania lanzan extract at 100, 200 and 300 mg/kg and disodium cromoglycate were given orally 1 hr prior to compound 48/80.Mortality was monitored for 1 hr after induction of anaphylactic reaction in animals on those bases to check the percent of protection17.7.3.5 Measurement of nitric oxide released by mast cell:The nitric oxide will be assayed by measuring nitrite the primary, stable and non- volatile breakdown product of NO. The Griess reagent uses N-1-napthylethylene diamine dihydrochloride (NED) and sulphanilamide under acidic condition in the presence of nitrite to yield azo compound that can be measured 546 nm by Spectrophotometric method18.7.3.6 Statistical Evaluation: 4 The collected data will be evaluated by ANOVA method followed by Dunnett’s multiple comparison and Chi-square test for anaphylactic reaction carried for conclusion of result.7.4 Does the study require any investigations or interventions to be calculated on patients or other Humans/animals? If so please describe briefly Yes, For this study rats and mice will be used before withdrawing the peritoneal fluid from the rats will be sacrificed by deep anesthesia using anesthetic ether.7.5 Has ethical clearance been obtained from your institution in case of 7.2 and?Yes, The study is cleared from Institutional Animal Ethics Committee (IAEC). The copy is enclosed with this protocol.5 8. References:1. Kay A.B. Allergy and allergic diseases. N Eng J Med 2001;344:30,109.2. Shirwaikar A., Somashekar A.P. Anti-inflammatory activity and free radical scavenging studies of Aristolochia bracteata Lam. Pharmacol 2003;65(1):67-69.3. Bradley J.U., Lawrence M.L. Drugs used in the treatment of asthma, In: Goodman andGilman’s. The Pharmacological basis of therapeutics, Hardman JG., Limberd LE. 11th Ed. McGraw Hill Publication, New Delhi 2001;748-749.4. Arya R., Babu.V., Ilyas.M and Nasim.K.T. Myricetin-3-Rhamnoside-3-galactoside fromBuchanania lanzan Phytochemistry. MAPA 1992;31(7):2569-2570.5. Anupam Sengupta and Sajal K. Roychoudhury. Department of pharmacy, Jadavpur University,Culcutta-700032, India. J Sci Food Agri 1977;28(5):463-468. 6. Rajesh K., Mishra. Shambhu., P. Patel., Anupam Srivastava., Rajiv K. Vashistha., Ajay Singh and Ashok K. piskar. Ethnomedicinally important plants of Pachmarhi region, MadhyaPradesh, India. Nat Sci 2012;10(4):24. 7. Kirtikar KR and Basu BD. Indian Medicinal Plants. 2nd Edition. Dehradun: International BookDistributors, Book Sellers and Publishers 1999;2:1020-1023. 8. S. K. Mali., R. Chaudhury., N. S. Panwar., O. P. Dhariwal., Ravish Choudhary and SusheelKumar Genetic resources of Chironji (Buchanania lanzan Spreng.) Genet Resour Crop Evol2012;59:615-623. 9. Thatoi HN., Panda SK., Rath SK and Dutta SK. Antimicrobial activity of Ethnomedicinaluses of some Medicinal plants from Similipal Biosphere Reserve, Orissa. Asi Jou plant Sci2008;7(3):260-267. 10. Anju puri., Sahai R., Kiran L Singh., Saxena RP., Tandon JS and Saxena KC.Immunostimulant activity of dry fruits and plant materials used in Indian traditional medical system for mothers after child birth and invalids. J Ethnopharmacol 2000;71(200):89-92.11. Archana Kumari and Poonam Kakkar. Screening of Antioxidant potential of selected Barks of 6 Indian Medicinal plants by Multiple invitro Assays. Biomed Environment Sci 2008;21:24-29.12. Xue Y and Chen H. Study on the anti-carcinogenic effect of three compounds of Buchanania lanzan L, Xei Shen Yan Jiu 2002;31(4):247-248,251. 9. SIGNATURE OF CANDIDATE VIJAYKUMAR SHEVALEBuchnania lanzan Sperng. has been 10. REMARKS OF TH GUIDE mentioned as very good medicinal plant in various literatures, The present study was evaluated for its anti-allergic activity scientifically.11. NAME AND DESIGNATION OF THE Dr. I. S. MUCHCHANDI GUIDE Principal and professor12. SIGNATURE13. CO-GUIDE14. SIGNATURE15. HEAD OF THE DEPARTMENT Dr. I. S. MUCHCHANDI H.O.D., Department of Pharmacology H.S.K. College of Pharmacy, B.V.V.S. Campus, Bagalkot-587101.16. SIGNATURE17. REMARKS OF THE The above mentioned information is correct PRINCIPAL and I recommended the same for approval.Dr. I.S.MUCHCHANDI 18. NAME OF THE PRINCIPAL H.O.D., Department of Pharmacology H.S.K. College of Pharmacy, B.V.V.S. Campus, Bagalkot-587101.19. SIGNATURE7 OFFICE OF THE INSTITUTIONAL ANIMAL ETHICS COMMITTEE (IAEC) HANAGAL SHRI KUMARESHWAR COLLEGE OF PHARMACY, BAGALKOT-587101, KARNATAKAREG NO.821/01/a/CPCSEA, Dated: 6th AUG 2004 UNDER THE RULES 5(a) OF THE “BREEDING OF AND EXPERIMENTS ON ANIMALS (Control and Supervision) RULES 1998”Ref: HSKCP/IAEC, Clear / 2009-10/1-8CERTIFICATEThis is to certify that Mr.VIJAYKUMAR SHEVALE. A student of firstM.Pharm is permitted to carry out experiments on animals for the dissertation / thesis work entitled as “Anti-allergic activity of Buchnania lanzan Spreng. In mast cell mediated allergic models” per details mentioned and after observing the usual formalities laid down by IAEC as per provision made by CPCSEA. Animal house in charge CHAIRMAN8FORM B See rule [6 (a) and 8(a)] PART A(1) Name and address of the Establishment: H.S.K. COLLEGE OF PHARMACY BAGALKOT, KARNATAKA. INDIA.(2) Date and Registration Number of the 821/01/a CPCSEA. Establishment:(3) Name, address and Registration NO. of the OFFICE OF CPCSEA, breeder from whom acquired and the date of MINISTRY OF ENVIROMENT AND FOREST, acquisition: 3rd SEAWARD ROAD, VALMIKINAGAR, THRIRUVANMIYUR, CHENNAI-600041.ANIMAL HOUSE (4) Place where the animals are presently kept: H.S.K. COLLEGE OF PHARMACY BAGALKOT, KARNATAKA.DEPARTMENT OF PHARMACOLOGY (5) Place where the experiment is to be H.S.K. COLLEGE OF PHARMACY performed: BAGALKOT, KARNATAKA.(6) The date on which the experiment is to commence and the duration of the 15 MAY 2013, (6 months). experiment:The protocol form for the research proposal - PART B in the case of experiments using other than non-human primate animals for new projects, PART C for use of non-human primates for new projects and PART D for use of non-human primate for extension of ongoing projects – should be duly filled, singed and annexed with this form.Dated: SignaturePlace: (Name and Designation)9PART – BProtocol form for Research Proposal to be submitted to the Committee on use of small animals / animals other than non human primate in Biomedical Research for NEW PROJECTS1. Project Title : Anti allergic activity of Buchnania lanzan Spreng. In mast cell mediated allergic models.2. Investigation (s) : Dr. I.S. Muchchandi Designation Principal and professor3. Department (s) : DEPARTMENT OF PHARMACOLOGY H.S.K. COLLAGE OF PHARMACY BAGALKOT, KARNATAKA.4. (a) Funding Source (s): if any ----(b) Are sufficient funds available for purchase and maintenance of the animals yes(C) Duration of present project :(1) Number of months : 6 months(2) Date of start of the Project : (Experiment) 15th May 2013(3) Date of termination of the project : 15th Dec 20135. Date by which approval is needed in case the project is to be funded by outside ---- agency (If less than six weeks from the date of admission, please justify below).10 6. Summary of project briefly summarize in laymen’s term the background, the objective and the experiment approach.(a) Background Enclosed(b) Objectives Enclosed(c) Experimental procedure: Enclosed7. (a) Name of species Swiss Albino (Mice)Spague-Dawley ( rats) Age Sex Weight Rat Mice Rat Mice4-6 weeks 2-5 weeks Male 200-250 g 20-25 g (b) Rationale for selectionApproximate number of animals required during the 80 first 12 months.Justification of number (define treatment group and Fifteen groups, Each group containing six animals. number per group)Number of animals housed per weeks 208. List all invasive Non Surgical Animal Procedures and Invasive surgical animal Potentially Stressful Noninvasive procedures to be used procedures. (Example IM injection, foot pad injection, venapunctures).Procedure and Approximate Frequency: Enclosed11 Anesthetic and/or Analgesic and Dosage:Not applicable.Test substance injected and/or applied:Test substance will administer post Orally.9. Does the protocol prohibit the use of anesthetic and analgesic for the conduct of painful procedures?No.10. With surgical procedure/Experimental procedure is performed?No.(a) Will the animal be sacrificed after surgery?No.(b) Give anticipated post operative survival time:---- 11. Will hazardous agent such as radioisotopes, carcinogens, radiation exposure, microbial and parasitic agent be administered to animals?NoINVESTIGATOR SIGNATUREDATE______12

Anti-Allergic Activity of Matricuria Recutit Linn

Details

Download

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

Support